Difference between revisions of "Staging page"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
m (Blanked the page)
Tag: Blanking
 
(24 intermediate revisions by 2 users not shown)
Line 1: Line 1:
−
<span id="BackToTop"></span>
+
 
−
<div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px; opacity:0.8; border-style: solid; border-color:DarkGray; border-width: 1px">
 
−
[[#top|Back to Top]]
 
−
</div>
 
−
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the [http://www.nccn.org/professionals/physician_gls/f_guidelines.asp NCCN Guidelines]. Is there a regimen missing from this list? See the [[Hodgkin_lymphoma|main Hodgkin lymphoma page]] for current regimens.
 
−
{| class="wikitable" style="float:right; margin-right: 5px;"
 
−
|-
 
−
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]]  |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
 
−
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]]  |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
 
−
|}
 
−
{{TOC limit|limit=3}}
 
−
=Untreated=
 
−
==ABVDm {{#subobject:3065be|Regimen=1}}==
 
−
ABVDm: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>V</u>'''inblastine, '''<u>D</u>'''acarbazine, '''<u>m</u>'''ethylprednisolone
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:c39ab4|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
−
|-
 
−
|[http://www.bloodjournal.org/content/103/1/58.long Le Maignan et al. 2003 (H90-NM)]
 
−
|1990-1996
 
−
| style="background-color:#1a9851" |Phase 3 (C)
 
−
|[[#EBVMm_99|EBVMm]]
 
−
| style="background-color:#ffffbf" |Seems not superior
 
−
|-
 
−
|}
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Doxorubicin (Adriamycin)]]
 
−
*[[Bleomycin (Blenoxane)]]
 
−
*[[Vinblastine (Velban)]]
 
−
*[[Dacarbazine (DTIC)]]
 
−
====Glucocorticoid therapy====
 
−
*[[Methylprednisolone (Solumedrol)]]
 
−
</div></div>
 
−
===References===
 
−
# '''H90-NM:''' Le Maignan C, Desablens B, Delwail V, Dib M, Berthou C, Vigier M, Ghandour C, Atmani S, Casassus P, Maisonneuve H, Le Mevel A, Traulle C, Bernard M, Briere J, Colonna P, Andrieu JM. Three cycles of adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) or epirubicin, bleomycin, vinblastine, and methotrexate (EBVM) plus extended field radiation therapy in early and intermediate Hodgkin disease: 10-year results of a randomized trial. Blood. 2004 Jan 1;103(1):58-66. Epub 2003 Aug 7. [http://www.bloodjournal.org/content/103/1/58.long link to original article] [https://pubmed.ncbi.nlm.nih.gov/12907440 PubMed]
 
−
==ABVE-PC {{#subobject:c24d93|Regimen=1}}==
 
−
ABVE-PC: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>V</u>'''incristine, '''<u>E</u>'''toposide, '''<u>P</u>'''rednisone, '''<u>C</u>'''yclophosphamide
 
−
</div></div><br>
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen variant #2, 3 cycles with response adaptation {{#subobject:14cd95|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
! style="width: 25%" |Study
 
−
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2744567/ Schwartz et al. 2009 (POG P9425)]
 
−
| style="background-color:#91cf61" |Phase 2
 
−
|-
 
−
|}''This regimen is intended for pediatric patients, younger than 22 years old. Note that first day of chemotherapy is day 0. Bleomycin and prednisone dosing is post-amendment.''
 
−
====Chemotherapy====
 
−
*[[Doxorubicin (Adriamycin)]] 30 mg/m<sup>2</sup> IV once per day on days 0 & 1
 
−
*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV or SC once per day on days 0 & 7
 
−
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2.8 mg) IV once per day on days 0 & 7
 
−
*[[Etoposide (Vepesid)]] 75 mg/m<sup>2</sup> IV once per day on days 0 to 4
 
−
*[[Cyclophosphamide (Cytoxan)]] 800 mg/m<sup>2</sup> IV once on day 0
 
−
====Glucocorticoid therapy====
 
−
*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 0 to 7
 
−
====Supportive therapy====
 
−
*[[Dexrazoxane (Zinecard)]] 300 mg/m<sup>2</sup> IV once per day on days 0, 1, 7 (this was a randomization)
 
−
*[[Filgrastim (Neupogen)]] 5 mcg/kg IV or SC once per day from day 5 until neutrophil recovery (held on day 7)
 
−
'''21-day cycle for 3 cycles'''
 
−
</div>
 
−
<div class="toccolours" style="background-color:#cbd5e7">
 
−
====Subsequent treatment====
 
−
*Rapid early responders: [[#Radiation_therapy_2|IFRT]] consolidation x 21 Gy
 
−
*Slow early responders: [[#ABVE-PC|ABVE-PC]] x 2 (5 cycles total), then [[#Radiation_therapy_2|IFRT]] consolidation x 21 Gy
 
−
</div></div><br>
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen variant #4, 5 cycles {{#subobject:7e95ea|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
! style="width: 25%" |Study
 
−
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2744567/ Schwartz et al. 2009 (POG P9425)]
 
−
| style="background-color:#91cf61" |Phase 2
 
−
|-
 
−
|}''This regimen is intended for pediatric patients, younger than 22 years old, who are slow early responders. Note that first day of chemotherapy is day 0. Bleomycin and prednisone dosing is post-amendment.''
 
−
<div class="toccolours" style="background-color:#cbd5e8">
 
−
====Preceding treatment====
 
−
*[[#ABVE-PC|ABVE-PC]] x 3, with slow early response
 
−
</div>
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Doxorubicin (Adriamycin)]] 30 mg/m<sup>2</sup> IV once per day on days 0 & 1
 
−
*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV or SC once per day on days 0 & 7
 
−
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2.8 mg) IV once per day on days 0 & 7
 
−
*[[Etoposide (Vepesid)]] 75 mg/m<sup>2</sup> IV once per day on days 0 to 4
 
−
*[[Cyclophosphamide (Cytoxan)]] 800 mg/m<sup>2</sup> IV once on day 0
 
−
====Glucocorticoid therapy====
 
−
*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 0 to 7
 
−
====Supportive therapy====
 
−
*[[Dexrazoxane (Zinecard)]] 300 mg/m<sup>2</sup> IV once per day on days 0, 1, 7 (this was a randomization)
 
−
*[[Filgrastim (Neupogen)]] 5 mcg/kg IV or SC once per day from day 5 until neutrophil recovery (held on day 7)
 
−
'''21-day cycle for 5 cycles, including the first 3 cycles'''
 
−
</div>
 
−
<div class="toccolours" style="background-color:#cbd5e7">
 
−
====Subsequent treatment====
 
−
*[[#Radiation_therapy_2|IFRT]] consolidation x 21 Gy
 
−
</div></div>
 
−
===References===
 
−
#'''POG P9425:''' Schwartz CL, Constine LS, Villaluna D, London WB, Hutchison RE, Sposto R, Lipshultz SE, Turner CS, deAlarcon PA, Chauvenet A. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood. 2009 Sep 3;114(10):2051-9. Epub 2009 Jul 7. Erratum: in Blood 2016 128:605 [http://www.bloodjournal.org/content/114/10/2051.long link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2744567/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/19584400 PubMed] NCT00005578
 
−
==BCVPP {{#subobject:75779b|Regimen=1}}==
 
−
BCVPP: '''<u>B</u>'''CNU (Carmustine), '''<u>C</u>'''yclophosphamide, '''<u>V</u>'''incristine, '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:ab3db2|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
−
|-
 
−
|[https://doi.org/10.1002/1097-0142%28197811%2942%3A5%3C2101%3A%3AAID-CNCR2820420504%3E3.0.CO%3B2-M Durant et al. 1978]
 
−
|1971-1975
 
−
| style="background-color:#91cf61" |Non-randomized portion of RCT
 
−
| style="background-color:#d3d3d3" |
 
−
| style="background-color:#d3d3d3" |
 
−
|-
 
−
|[https://doi.org/10.7326/0003-4819-101-4-447 Bakemeier et al. 1984]
 
−
|1972-1976
 
−
|style="background-color:#1a9851"|Phase 3 (E-esc)
 
−
|[[Hodgkin_lymphoma#MOPP|MOPP]]
 
−
|style="background-color:#ffffbf"|Seems not superior<sup>1</sup>
 
−
|-
 
−
|}
 
−
''<sup>1</sup>For patients achieving CR, this regimen seemed to have comparatively superior survival.''
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Carmustine (BCNU)]]
 
−
*[[Cyclophosphamide (Cytoxan)]]
 
−
*[[Vincristine (Oncovin)]]
 
−
*[[Procarbazine (Matulane)]]
 
−
====Glucocorticoid therapy====
 
−
*[[Prednisone (Sterapred)]]
 
−
</div></div>
 
−
===References===
 
−
# Durant JR, Gams RA, Velez-Garcia E, Bartolucci A, Wirtschafter D, Dorfman R. BCNU, velban, cyclophosphamide, procarbazine, and prednisone (BVCPP) in advanced Hodgkin's disease. Cancer. 1978 Nov;42(5):2101-10. [https://doi.org/10.1002/1097-0142%28197811%2942%3A5%3C2101%3A%3AAID-CNCR2820420504%3E3.0.CO%3B2-M link to original article] [https://pubmed.ncbi.nlm.nih.gov/719600 PubMed]
 
−
# Bakemeier RF, Anderson JR, Costello W, Rosner G, Horton J, Glick JH, Hines JD, Berard CW, DeVita VT Jr; [[Study_Groups#ECOG|ECOG]]. BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen: results of the Eastern Cooperative Oncology Group study. Ann Intern Med. 1984 Oct;101(4):447-56. [https://doi.org/10.7326/0003-4819-101-4-447 link to original article] [https://pubmed.ncbi.nlm.nih.gov/6089632 PubMed]
 
−
==ChlVPP/PABIOE {{#subobject:8ee324|Regimen=1}}==
 
−
ChlVPP/PABIOE: '''<u>Chl</u>'''orambucil, '''<u>V</u>'''inblastine, '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone alternating with '''<u>P</u>'''rednisolone, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>O</u>'''ncovin (Vincristine), '''<u>E</u>'''toposide
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Protocol {{#subobject:48feb0|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
−
|-
 
−
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363648/ Hancock et al. 2001]
 
−
|1992-1996
 
−
| style="background-color:#1a9851" |Randomized (C)
 
−
|[[#PABIOE_99|PABIOE]]
 
−
| style="background-color:#1a9850" |Superior OS
 
−
|-
 
−
|}
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy, ChlVPP portion====
 
−
*[[Chlorambucil (Leukeran)]]
 
−
*[[Vinblastine (Velban)]]
 
−
*[[Procarbazine (Matulane)]]
 
−
====Glucocorticoid therapy, ChlVPP portion====
 
−
*[[Prednisolone (Millipred)]]
 
−
====Glucocorticoid therapy, PABIOE portion====
 
−
*[[Prednisolone (Millipred)]]
 
−
====Chemotherapy, PABIOE portion====
 
−
*[[Doxorubicin (Adriamycin)]]
 
−
*[[Bleomycin (Blenoxane)]]
 
−
*[[Vincristine (Oncovin)]]
 
−
*[[Etoposide (Vepesid)]]
 
−
</div></div>
 
−
===References===
 
−
# Hancock BW, Gregory WM, Cullen MH, Hudson GV, Burton A, Selby P, Maclennan KA, Jack A, Bessell EM, Smith P, Linch DC; British National Lymphoma Investigation; Central Lymphoma Group. ChlVPP alternating with PABlOE is superior to PABlOE alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation/Central Lymphoma Group randomized controlled trial. Br J Cancer. 2001 May 18;84(10):1293-300. [https://doi.org/10.1054/bjoc.2001.1778 link to orginal article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363648/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/11355937 PubMed]
 
−
# '''UKLG LY09:''' Johnson PW, Radford JA, Cullen MH, Sydes MR, Walewski J, Jack AS, MacLennan KA, Stenning SP, Clawson S, Smith P, Ryder D, Hancock BW; United Kingdom Lymphoma Group. Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). J Clin Oncol. 2005 Dec 20;23(36):9208-18. Epub 2005 Nov 28. [https://doi.org/10.1200/JCO.2005.03.2151 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/16314615 PubMed] ISRCTN97144519
 
−
## '''Subgroup analysis:''' Johnson PW, Sydes MR, Hancock BW, Cullen M, Radford JA, Stenning SP. Consolidation radiotherapy in patients with advanced Hodgkin's lymphoma: survival data from the UKLG LY09 randomized controlled trial (ISRCTN97144519). J Clin Oncol. 2010 Jul 10;28(20):3352-9. Epub 2010 May 24. [https://doi.org/10.1200/JCO.2009.26.0323 link to original article] [https://pubmed.ncbi.nlm.nih.gov/20498402 PubMed]
 
−
==COMP {{#subobject:8ee324|Regimen=1}}==
 
−
COMP: '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>M</u>'''ethotrexate, '''<u>P</u>'''rednisone
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:48feb0|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
!style="width: 25%"|Study
 
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[http://cancerres.aacrjournals.org/content/27/7/1258.long Moxley et al. 1967]
 
−
| style="background-color:#ffffbe" |Pilot
 
−
|-
 
−
|}
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Cyclophosphamide (Cytoxan)]]
 
−
*[[Vincristine (Oncovin)]]
 
−
*[[Methotrexate (MTX)]]
 
−
====Glucocorticoid therapy====
 
−
*[[Prednisone (Sterapred)]]
 
−
</div></div>
 
−
===References===
 
−
# Moxley JH 3rd, De Vita VT, Brace K, Frei E 3rd. Intensive combination chemotherapy and X-irradiation in Hodgkin's disease. Cancer Res. 1967 Jul;27(7):1258-63. [http://cancerres.aacrjournals.org/content/27/7/1258.long link to original article] [https://pubmed.ncbi.nlm.nih.gov/4952914 PubMed]
 
−
==COPP (CCNU) {{#subobject:86879b|Regimen=1}}==
 
−
COPP: '''<u>C</u>'''CNU (Lomustine), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:cf3db2|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
−
|-
 
−
|rowspan=3|[https://doi.org/10.1002/1097-0142(19800815)46:4%3C654::AID-CNCR2820460405%3E3.0.CO;2-A Cooper et al. 1980]
 
−
|rowspan=3|1972-1975
 
−
|rowspan=3 style="background-color:#1a9851"|Phase 3 (E-switch-ic)
 
−
|1. [[#CVPP|CVPP]]
 
−
|style="background-color:#ffffbf"|Seems not superior
 
−
|-
 
−
|2. [[Hodgkin_lymphoma#MOPP|MOPP]]
 
−
|style="background-color:#ffffbf"|Seems not superior
 
−
|-
 
−
|3. [[#MVPP|MVPP]]
 
−
|style="background-color:#ffffbf"|Seems not superior
 
−
|-
 
−
|}
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Lomustine (CCNU)]]
 
−
*[[Vincristine (Oncovin)]]
 
−
*[[Procarbazine (Matulane)]]
 
−
====Glucocorticoid therapy====
 
−
*[[Prednisone (Sterapred)]]
 
−
</div></div>
 
−
===References===
 
−
# Cooper MR, Pajak TF, Nissen NI, Stutzman L, Brunner K, Cuttner J, Falkson G, Grunwald H, Bank A, Leone L, Seligman BR, Silver RT, Weiss RB, Haurani F, Blom J, Spurr CL, Glidewell OJ, Gottlieb AJ, Holland JF. A new effective four-drug combination of CCNU (1-[2-chloroethyl]-3-cyclohexyl-1-nitrosourea) (NSC-79038), vinblastine, prednisone, and procarbazine for the treatment of advanced Hodgkin's disease. Cancer. 1980 Aug 15;46(4):654-62. [https://doi.org/10.1002/1097-0142(19800815)46:4%3C654::AID-CNCR2820460405%3E3.0.CO;2-A link to original article] [https://pubmed.ncbi.nlm.nih.gov/7397630 PubMed]
 
−
==COPP/ABVD {{#subobject:92a2c8|Regimen=1}}==
 
−
COPP/ABVD: '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone alternating with '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>V</u>'''inblastine, '''<u>D</u>'''acarbazine
 
−
<br>C-MOPP/ABVD: '''<u>C</u>'''yclophospha'''<u>M</u>'''ide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone alternating with '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>V</u>'''inblastine, '''<u>D</u>'''acarbazine
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Protocol variant #1, 4 cycles {{#subobject:771e81|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
−
|-
 
−
|[https://doi.org/10.1200/JCO.2002.20.2.476 Sieber et al. 2002 (GHSG HD5)]
 
−
|1988-1993
 
−
|style="background-color:#1a9851"|Phase 3 (C)
 
−
|[[#COPP.2FABV.2FIMEP_99|COPP/ABV/IMEP]]
 
−
|style="background-color:#ffffbf"|Seems not superior
 
−
|-
 
−
|[https://doi.org/10.1093/annonc/mdh046 Sieber et al. 2004 (GHSG HD6)]
 
−
|1988-1993
 
−
|style="background-color:#1a9851"|Phase 3 (C)
 
−
|[[#COPP.2FABV.2FIMEP_99|COPP/ABV/IMEP]]
 
−
|style="background-color:#ffffbf"|Seems not superior
 
−
|-
 
−
|[https://doi.org/10.1200/JCO.2003.03.023 Engert et al. 2003 (GHSG HD8)]
 
−
|1993-1998
 
−
|style="background-color:#91cf61"|Non-randomized portion of RCT
 
−
|style="background-color:#d3d3d3"|
 
−
|style="background-color:#d3d3d3"|
 
−
|-
 
−
|}
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy, COPP portion====
 
−
*[[Cyclophosphamide (Cytoxan)]]
 
−
*[[Vincristine (Oncovin)]]
 
−
*[[Procarbazine (Matulane)]]
 
−
====Glucocorticoid therapy, COPP portion====
 
−
*[[Prednisone (Sterapred)]]
 
−
'''28-day cycle for 2 total cycles of COPP, alternating with 2 total cycles of ABVD'''
 
−
====Chemotherapy, ABVD portion====
 
−
*[[Doxorubicin (Adriamycin)]]
 
−
*[[Bleomycin (Blenoxane)]]
 
−
*[[Vinblastine (Velban)]]
 
−
*[[Dacarbazine (DTIC)]]
 
−
'''28-day cycle for 2 total cycles of ABVD, alternating with 2 total cycles of COPP'''
 
−
</div>
 
−
<div class="toccolours" style="background-color:#cbd5e7">
 
−
====Subsequent treatment====
 
−
*GHSG HD5 & HD6: [[Hodgkin_lymphoma#Radiation_therapy_2|EFRT]]
 
−
*GHSG HD8: [[Hodgkin_lymphoma#Radiation_therapy_2|EFRT]] versus [[Hodgkin_lymphoma#Radiation_therapy_2|IFRT]]
 
−
</div></div><br>
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Protocol variant #2, 6 cycles {{#subobject:6d7f98|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
!style="width: 25%"|Study
 
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://doi.org/10.1093/oxfordjournals.annonc.a059357 Diehl et al. 1995 (GHSG HD3)]
 
−
|style="background-color:#91cf61"|Non-randomized portion of RCT
 
−
|-
 
−
|}
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy, COPP portion====
 
−
*[[Cyclophosphamide (Cytoxan)]]
 
−
*[[Vincristine (Oncovin)]]
 
−
*[[Procarbazine (Matulane)]]
 
−
====Glucocorticoid therapy, COPP portion====
 
−
*[[Prednisone (Sterapred)]]
 
−
'''28-day cycle for 3 total cycles of COPP, alternating with 3 total cycles of ABVD'''
 
−
====Chemotherapy, ABVD portion====
 
−
*[[Doxorubicin (Adriamycin)]]
 
−
*[[Bleomycin (Blenoxane)]]
 
−
*[[Vinblastine (Velban)]]
 
−
*[[Dacarbazine (DTIC)]]
 
−
'''28-day cycle for 3 total cycles of ABVD, alternating with 3 total cycles of COPP'''
 
−
</div>
 
−
<div class="toccolours" style="background-color:#cbd5e7">
 
−
====Subsequent treatment====
 
−
*COPP/ABVD x 1 (8 cycles total) versus IFRT
 
−
</div></div><br>
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Protocol variant #3, 10 cycles {{#subobject:faa63|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
−
|-
 
−
|[https://jjco.oxfordjournals.org/content/30/3/146.long Takenaka et al. 2000 (JCOG 8905)]
 
−
|1989-1993
 
−
|style="background-color:#91cf61"|Phase 2
 
−
|style="background-color:#d3d3d3"|
 
−
|style="background-color:#d3d3d3"|
 
−
|-
 
−
|[https://doi.org/10.1200/jco.1998.16.12.3810 Diehl et al. 1998 (GHSG HD9)]
 
−
|1993-1998
 
−
|style="background-color:#1a9851"|Phase 3 (C)
 
−
|1. [[Hodgkin_lymphoma#BEACOPP_2|BEACOPP]]<br>2. [[Hodgkin_lymphoma#eBEACOPP_2|eBEACOPP]]
 
−
|style="background-color:#fc8d59"|Seems to have inferior OS
 
−
|-
 
−
|[https://doi.org/10.1093/annonc/mdi023 Ballova et al. 2005 (GHSG HD9elderly)]
 
−
|1993-1998
 
−
|style="background-color:#1a9851"|Phase 3 (C)
 
−
|[[Hodgkin_lymphoma#BEACOPP_2|BEACOPP]]
 
−
|style="background-color:#ffffbf"|Seems not superior
 
−
|-
 
−
|}
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy, COPP portion====
 
−
*[[Cyclophosphamide (Cytoxan)]] as follows:
 
−
**Cycles 1, 3, 5, 7, 9: 500 mg/m<sup>2</sup> IV once per day on days 1 & 8
 
−
*[[Vincristine (Oncovin)]] as follows:
 
−
**Cycles 1, 3, 5, 7, 9: 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once per day on days 1 & 8
 
−
*[[Procarbazine (Matulane)]] as follows:
 
−
**Cycles 1, 3, 5, 7, 9: 100 mg/m<sup>2</sup> (maximum dose of 150 mg) PO once per day on days 1 to 14
 
−
====Glucocorticoid therapy, COPP portion====
 
−
*[[Prednisone (Sterapred)]] as follows:
 
−
**Cycles 1, 3, 5, 7, 9: 40 mg/m<sup>2</sup> PO once per day on days 1 to 3, 8 to 10
 
−
====Chemotherapy, ABVD portion====
 
−
*[[Doxorubicin (Adriamycin)]] as follows:
 
−
**Cycles 2, 4, 6, 8, 10: 25 mg/m<sup>2</sup> IV once per day on days 1 & 15
 
−
*[[Bleomycin (Blenoxane)]] as follows:
 
−
**Cycles 2, 4, 6, 8, 10: 9 mg/m<sup>2</sup> (maximum dose of 15 mg) IV once per day on days 1 & 15
 
−
*[[Vinblastine (Velban)]] as follows:
 
−
**Cycles 2, 4, 6, 8, 10: 6 mg/m<sup>2</sup> (maximum dose of 10 mg) IV once per day on days 1 & 15
 
−
*[[Dacarbazine (DTIC)]] as follows:
 
−
**Cycles 2, 4, 6, 8, 10: 250 mg/m<sup>2</sup> IV once per day on days 1 & 15
 
−
'''28-day cycle for 10 cycles'''
 
−
</div>
 
−
<div class="toccolours" style="background-color:#cbd5e7">
 
−
====Subsequent treatment====
 
−
*Some studies: [[Hodgkin_lymphoma#Radiation_therapy_2|IFRT]] x 30 Gy after completion of chemotherapy was given to patients with bulky (at least 10 cm maximum diameter) disease
 
−
====Dose modifications====
 
−
*Treatment was postponed for at least 1 week or until recovery if:
 
−
**Pretreatment ANC was less than 1500/uL
 
−
**Platelet count was less than 100 x 10<sup>9</sup>/L
 
−
**AST/S-GOT was greater than 100 IU/L
 
−
**Total bilirubin was greater than 2
 
−
*Vincristine and vinblastine were temporarily discontinued if patients had grade 2 or greater neurotoxicity (e.g. motor weakness, paresthesia, constipation)
 
−
*Doxorubicin was discontinued if cardiac LV ejection fraction was less than 50%
 
−
*Bleomycin was stopped if the PaO2 was less than 70 mmHg or if it decreased more than 10 mmHg from the previous measurement
 
−
*Note: Dacarbazine 250 mg/m<sup>2</sup> was used at this dose reduction based on experiences in a pilot study in which there was severe emesis with 375 mg/m<sup>2</sup>.
 
−
</div></div>
 
−
===References===
 
−
# '''GHSG HD3:''' Diehl V, Loeffler M, Pfreundschuh M, Ruehl U, Hasenclever D, Nisters-Backes H, Sieber M, Smith K, Tesch H, Geilen W, Adler M, Bartels H, Brandenburg U, Diezler P, Doelken G, Enzian J, Fuchs R, Gassmann W, Gerhartz H, Hagenaukamp U, Hecht T, Hiller E, Hinkelbein H, Lathan B, Kirchner H, Kuehn G, Kuerten H, Loos U, Makoski B, Oertel W, Petsch S, Pfab R, Pflueger H, Planker M, Rohioff R, Sack H, Samandari S, Sauer R, Schalk K, Schmitz G, Schoppe W, Schwieder G, Szepesi S, Teichmann J, Wilhelmy W, Worst P, Fischer R, Georgii A, Huebner E, Schwarze EW; German Hodgkin's Study Group. Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advance Hodgkin's disease. Ann Oncol. 1995 Nov;6(9):901-10. [https://doi.org/10.1093/oxfordjournals.annonc.a059357 link to original article] [https://pubmed.ncbi.nlm.nih.gov/8624293 PubMed]
 
−
# '''GHSG HD9:''' Diehl V, Franklin J, Hasenclever D, Tesch H, Pfreundschuh M, Lathan B, Paulus U, Sieber M, Rueffer JU, Sextro M, Engert A, Wolf J, Hermann R, Holmer L, Stappert-Jahn U, Winnerlein-Trump E, Wulf G, Krause S, Glunz A, von Kalle K, Bischoff H, Haedicke C, Duehmke E, Georgii A, Loeffler M. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 1998 Dec;16(12):3810-21. [https://doi.org/10.1200/jco.1998.16.12.3810 link to original article]'''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/9850026 PubMed]
 
−
## '''Update:''' Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, Tesch H, Herrmann R, Dörken B, Müller-Hermelink HK, Dühmke E, Loeffler M; German Hodgkin's Lymphoma Study Group. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med. 2003 Jun 12;348(24):2386-95. [https://doi.org/10.1056/NEJMoa022473 link to original article]'''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/12802024 PubMed]
 
−
## '''Update:''' Engert A, Diehl V, Franklin J, Lohri A, Dörken B, Ludwig WD, Koch P, Hänel M, Pfreundschuh M, Wilhelm M, Trümper L, Aulitzky WE, Bentz M, Rummel M, Sezer O, Müller-Hermelink HK, Hasenclever D, Löffler M. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009 Sep 20;27(27):4548-54. [https://doi.org/10.1200/jco.2008.19.8820 link to original article] [https://pubmed.ncbi.nlm.nih.gov/19704068 PubMed]
 
−
## '''Pooled update:''' von Tresckow B, Kreissl S, Dipl-Math HG, Bröckelmann PJ, Pabst T, Fridrik M, Rummel M, Jung W, Thiemer J, Sasse S, Bürkle C, Baues C, Diehl V, Engert A, Borchmann P; German Hodgkin Study Group. Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials. Lancet Haematol. 2018 Oct 01;5(10):e462-73. [https://doi.org/10.1016/S2352-3026(18)30140-6 link to original article] [https://pubmed.ncbi.nlm.nih.gov/30290903 PubMed]
 
−
# '''JCOG 8905:''' Takenaka T, Mikuni C, Miura A, Sasaki T, Suzuki H, Hotta T, Hirano M, Fukuhara S, Sugiyama H, Nasu K, Dohi H, Kozuru M, Tomonaga M, Tajima K, Niimi M, Fukuda H, Mukai K, Shimoyama M; Lymphoma Study Group of the Japan Clinical Oncology Group. Alternating combination chemotherapy C-MOPP (cyclophosphamide, vincristine, procarbazine, prednisone) and ABVd (adriamycin, bleomycin, vinblastine, dacarbazine) in clinical stage II-IV Hodgkin's disease: a multicenter phase II study (JCOG 8905). Jpn J Clin Oncol. 2000 Mar;30(3):146-52. [https://jjco.oxfordjournals.org/content/30/3/146.long link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/10798542 PubMed]
 
−
# '''GHSG HD5:''' Sieber M, Tesch H, Pfistner B, Rueffer U, Lathan B, Brosteanu O, Paulus U, Koch T, Pfreundschuh M, Loeffler M, Engert A, Josting A, Wolf J, Hasenclever D, Franklin J, Duehmke E, Georgii A, Schalk KP, Kirchner H, Doelken G, Munker R, Koch P, Herrmann R, Greil R, Anselmo AP, Diehl V. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5. J Clin Oncol. 2002 Jan 15;20(2):476-84. [https://doi.org/10.1200/JCO.2002.20.2.476 link to original article] [https://pubmed.ncbi.nlm.nih.gov/11786577 PubMed]
 
−
# '''GHSG HD8:''' Engert A, Schiller P, Josting A, Herrmann R, Koch P, Sieber M, Boissevain F, De Wit M, Mezger J, Duhmke E, Willich N, Muller RP, Schmidt BF, Renner H, Muller-Hermelink HK, Pfistner B, Wolf J, Hasenclever D, Loffler M, Diehl V; German Hodgkin's Lymphoma Study Group. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 2003 Oct 1;21(19):3601-8. Epub 2003 Aug 11. [https://doi.org/10.1200/JCO.2003.03.023 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/12913100 PubMed]
 
−
## '''Update:''' Sasse S, Klimm B, Görgen H, Fuchs M, Heyden-Honerkamp A, Lohri A, Koch O, Wilhelm M, Trenn G, Finke J, Müller RP, Diehl V, Eich HT, Borchmann P, Engert A; German Hodgkin Study Group (GHSG). Comparing long-term toxicity and efficacy of combined modality treatment including extended- or involved-field radiotherapy in early-stage Hodgkin's lymphoma. Ann Oncol. 2012 Nov;23(11):2953-9. Epub 2012 Jul 5. [https://doi.org/10.1093/annonc/mds110 link to original article] [https://pubmed.ncbi.nlm.nih.gov/22767583 PubMed]
 
−
## '''Update:''' Sasse S, Bröckelmann PJ, Goergen H, Plütschow A, Müller H, Kreissl S, Buerkle C, Borchmann S, Fuchs M, Borchmann P, Diehl V, Engert A. Long-term follow-up of contemporary treatment in early-stage Hodgkin lymphoma: updated analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 trials. J Clin Oncol. 2017 Jun 20;35(18):1999-2007. Epub 2017 Apr 18. [https://doi.org/10.1200/JCO.2016.70.9410 link to original article] [https://pubmed.ncbi.nlm.nih.gov/28418763 PubMed]
 
−
# '''GHSG HD6:''' Sieber M, Tesch H, Pfistner B, Rueffer U, Paulus U, Munker R, Hermann R, Doelken G, Koch P, Oertel J, Roller S, Worst P, Bischof H, Glunz A, Greil R, von Kalle K, Schalk KP, Hasenclever D, Brosteanu O, Duehmke E, Georgii A, Engert A, Loeffler M, Diehl V, Mueller RP, Willich N, Fischer R, Hansmann ML, Stein H, Schober T, Koch B; German Hodgkin's Lymphoma Study Group. Treatment of advanced Hodgkin's disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin's Lymphoma Study Group HD6 trial. Ann Oncol. 2004 Feb;15(2):276-82. [https://doi.org/10.1093/annonc/mdh046 link to original article] [https://pubmed.ncbi.nlm.nih.gov/14760122 PubMed]
 
−
# '''GHSG HD9elderly:''' Ballova V, Rüffer JU, Haverkamp H, Pfistner B, Müller-Hermelink HK, Dühmke E, Worst P, Wilhelmy M, Naumann R, Hentrich M, Eich HT, Josting A, Löffler M, Diehl V, Engert A. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann Oncol. 2005 Jan;16(1):124-31. [https://doi.org/10.1093/annonc/mdi023 link to original article]'''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/15598949 PubMed]
 
−
==CVPP {{#subobject:be8f99|Regimen=1}}==
 
−
CVPP: '''<u>C</u>'''CNU (Lomustine), '''<u>V</u>'''inblastine, '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:e71c98|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
−
|-
 
−
|rowspan=3|[https://doi.org/10.1002/1097-0142(19800815)46:4%3C654::AID-CNCR2820460405%3E3.0.CO;2-A Cooper et al. 1980]
 
−
|rowspan=3|1972-1975
 
−
|rowspan=3 style="background-color:#1a9851"|Phase 3 (E-switch-ic)
 
−
|1. [[#COPP_.28CCNU.29|COPP]]
 
−
|style="background-color:#ffffbf"|Seems not superior
 
−
|-
 
−
|2. [[Hodgkin_lymphoma#MOPP|MOPP]]
 
−
|style="background-color:#91cf60"|Seems to have superior CR rate
 
−
|-
 
−
|3. [[#MVPP|MVPP]]
 
−
|style="background-color:#ffffbf"|Seems not superior
 
−
|-
 
−
|[https://academic.oup.com/jnci/article-abstract/80/18/1466/943469 Pavlovsky et al. 1988]
 
−
|1977-1986
 
−
|style="background-color:#1a9851"|Randomized (E-de-esc)
 
−
|[[#CVPP_.26_88|CVPP & RT]]
 
−
| style="background-color:#d73027" |Inferior FFS<sup>1</sup>
 
−
|-
 
−
|[https://doi.org/10.1200/JCO.1997.15.7.2652 Pavlovsky et al. 1997]
 
−
|1986-NR
 
−
|style="background-color:#1a9851"|Randomized (C)
 
−
|[[#AOPE_99|AOPE]]
 
−
|style="background-color:#91cf60"|Seems to have superior CR rate
 
−
|-
 
−
|[https://doi.org/10.1002/(SICI)1096-911X(199712)29:6%3C544::AID-MPO5%3E3.0.CO;2-K Sackmann-Muriel et al. 1997]
 
−
|1987-1994
 
−
|style="background-color:#1a9851"|Randomized (C)
 
−
|[[#AOPE_99|AOPE]]
 
−
|style="background-color:#91cf60"|Seems to have superior EFS
 
−
|-
 
−
|}
 
−
''<sup>1</sup>No advantage was seen for either arm in the favorable prognosis group, whereas this arm had inferior DFS for the unfavorable prognosis group.''
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Lomustine (CCNU)]]
 
−
*[[Vinblastine (Velban)]]
 
−
*[[Procarbazine (Matulane)]]
 
−
====Glucocorticoid therapy====
 
−
*[[Prednisone (Sterapred)]]
 
−
</div></div>
 
−
===References===
 
−
# Cooper MR, Pajak TF, Nissen NI, Stutzman L, Brunner K, Cuttner J, Falkson G, Grunwald H, Bank A, Leone L, Seligman BR, Silver RT, Weiss RB, Haurani F, Blom J, Spurr CL, Glidewell OJ, Gottlieb AJ, Holland JF. A new effective four-drug combination of CCNU (1-[2-chloroethyl]-3-cyclohexyl-1-nitrosourea) (NSC-79038), vinblastine, prednisone, and procarbazine for the treatment of advanced Hodgkin's disease. Cancer. 1980 Aug 15;46(4):654-62. [https://doi.org/10.1002/1097-0142(19800815)46:4%3C654::AID-CNCR2820460405%3E3.0.CO;2-A link to original article] [https://pubmed.ncbi.nlm.nih.gov/7397630 PubMed]
 
−
# Pavlovsky S, Maschio M, Santarelli MT, Sackmann Muriel F, Corrado C, Garcia I, Schwartz L, Montero C, Lobo Sanahuja F, Magnasco O, Raha R, Cavagnaro F. Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I-II Hodgkin's disease. J Natl Cancer Inst. 1988 Nov 16;80(18):1466-73. [https://academic.oup.com/jnci/article-abstract/80/18/1466/943469 link to original article] [https://pubmed.ncbi.nlm.nih.gov/3184196 PubMed]
 
−
## '''Update:''' Pavlovsky S, Santarelli MT, Sackmann Muriel F, Fernández I, Garcia I, Schwartz L, Montero C, Sanahuja FL, Magnasco H, Costa A, Corrado C, Raha R, Bezares R. Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage III-IV A & B Hodgkin's disease. Ann Oncol. 1992 Jul;3(7):533-7. [https://doi.org/10.1093/oxfordjournals.annonc.a058255 link to original article] [https://pubmed.ncbi.nlm.nih.gov/1498073 PubMed]
 
−
# Pavlovsky S, Schvartzman E, Lastiri F, Magnasco H, Corrado C, Raslawski E, Cancela ME, Ardaiz MC, Cerutti I, Rosso A, Bruno S, Aranguren PN, Salvarezza A, Donato H, Dibar E, Zirone S; GATLA. Randomized trial of CVPP for three versus six cycles in favorable-prognosis and CVPP versus AOPE plus radiotherapy in intermediate-prognosis untreated Hodgkin's disease. J Clin Oncol. 1997 Jul;15(7):2652-8. [https://doi.org/10.1200/JCO.1997.15.7.2652 link to original article] [https://pubmed.ncbi.nlm.nih.gov/9215837 PubMed]
 
−
# Sackmann-Muriel F, Zubizarreta P, Gallo G, Scopinaro M, Alderete D, Alfaro E, Casak S, Chantada G, Felice MS, Quinteros R. Hodgkin disease in children: results of a prospective randomized trial in a single institution in Argentina. Med Pediatr Oncol. 1997 Dec;29(6):544-52. [https://doi.org/10.1002/(SICI)1096-911X(199712)29:6%3C544::AID-MPO5%3E3.0.CO;2-K link to original article] [https://pubmed.ncbi.nlm.nih.gov/9324342 PubMed]
 
−
==Doxorubicin & Vinblastine {{#subobject:66828f|Regimen=1}}==
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:597e32|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
−
|-
 
−
|[https://doi.org/10.1200/JCO.2001.19.22.4238 Press et al. 2001 (SWOG S9133)]
 
−
|1992-2000
 
−
|style="background-color:#1a9851"|Phase 3 (E-esc)
 
−
|[[#Radiation_therapy_88|STLI]]
 
−
| style="background-color:#1a9850" |Superior PFS
 
−
|-
 
−
|}
 
−
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once per day on days 1 & 15
 
−
*[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> IV once per day on days 1 & 15
 
−
'''28-day cycle for 3 cycles'''
 
−
</div>
 
−
<div class="toccolours" style="background-color:#cbd5e7">
 
−
====Subsequent treatment====
 
−
*STLI
 
−
</div></div>
 
−
===References===
 
−
# '''SWOG S9133:''' Press OW, LeBlanc M, Lichter AS, Grogan TM, Unger JM, Wasserman TH, Gaynor ER, Peterson BA, Miller TP, Fisher RI. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. J Clin Oncol. 2001 Nov 15;19(22):4238-44. [https://doi.org/10.1200/JCO.2001.19.22.4238 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/11709567 PubMed] NCT00002495
 
−
==LOPP {{#subobject:f2a168|Regimen=1}}==
 
−
LOPP: '''<u>L</u>'''eukeran (Chlorambucil), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:bfcf5a|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
−
|-
 
−
|[https://doi.org/10.1016/s0167-8140(86)80032-9 Hancock 1986]
 
−
|1979-NR
 
−
| style="background-color:#1a9851" |Randomized (E-switch-ic)
 
−
|[[Hodgkin_lymphoma#MOPP|MOPP]]
 
−
| style="background-color:#ffffbf" |Seems not superior
 
−
|-
 
−
|[https://doi.org/10.1200/JCO.1992.10.8.1252 Hancock et al. 1992]
 
−
|1983-1989
 
−
| style="background-color:#1a9851" |Randomized (C)
 
−
|[[#LOPP.2FEVAP|LOPP/EVAP]]
 
−
| style="background-color:#fc8d59" |Seems to have inferior OS
 
−
|-
 
−
|}
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Chlorambucil (Leukeran)]]
 
−
*[[Vincristine (Oncovin)]]
 
−
*[[Procarbazine (Matulane)]]
 
−
====Glucocorticoid therapy====
 
−
*[[Prednisone (Sterapred)]]
 
−
</div></div>
 
−
===References===
 
−
# Hancock BW; British National Lymphoma Investigation. Randomised study of MOPP (mustine, Oncovin, procarbazine, prednisone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease. Radiother Oncol. 1986 Nov;7(3):215-21. [https://doi.org/10.1016/s0167-8140(86)80032-9 link to original article] [https://pubmed.ncbi.nlm.nih.gov/3544084 PubMed]
 
−
## '''Update:''' Hancock BW, Vaughan Hudson G, Vaughan Hudson B, Haybittle JL, Bennett MH, MacLennan KA, Jelliffe AM; BNLI. British National Lymphoma Investigation randomised study of MOPP (mustine, Oncovin, procarbazine, prednisolone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease--long term results. Br J Cancer. 1991 Apr;63(4):579-82. [https://doi.org/10.1038/bjc.1991.134 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1972355/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/2021542 PubMed]
 
−
# Hancock BW, Vaughan Hudson G, Vaughan Hudson B, Bennett MH, MacLennan KA, Haybittle JL, Anderson L, Linch DC; BNLI. LOPP alternating with EVAP is superior to LOPP alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation trial. J Clin Oncol. 1992 Aug;10(8):1252-8. [https://doi.org/10.1200/JCO.1992.10.8.1252 link to original article] [https://pubmed.ncbi.nlm.nih.gov/1634914 PubMed]
 
−
==LOPP/EVAP {{#subobject:22b023|Regimen=1}}==
 
−
LOPP/EVAP: '''<u>L</u>'''eukeran (Chlorambucil), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone alternating with '''<u>E</u>'''toposide, '''<u>V</u>'''inblastine, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>P</u>'''rednisone
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Protocol {{#subobject:53f4da|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
−
|-
 
−
|[https://doi.org/10.1200/JCO.1992.10.8.1252 Hancock et al. 1992]
 
−
|1983-1989
 
−
| style="background-color:#1a9851" |Randomized (E-switch-ic)
 
−
|[[#LOPP|LOPP]]
 
−
| style="background-color:#91cf60" |Seems to have superior OS
 
−
|-
 
−
|[https://doi.org/10.1093/annonc/5.suppl_2.s117 Hancock et al. 1994]
 
−
|1990-1991
 
−
| style="background-color:#1a9851" |Randomized (C)
 
−
|[[#LOPP-EVA_99|LOPP-EVA]]
 
−
| style="background-color:#1a9850" |Superior CR rate
 
−
|-
 
−
|}
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy, LOPP portion====
 
−
*[[Chlorambucil (Leukeran)]]
 
−
*[[Vincristine (Oncovin)]]
 
−
*[[Procarbazine (Matulane)]]
 
−
====Glucocorticoid therapy, LOPP portion====
 
−
*[[Prednisone (Sterapred)]]
 
−
====Chemotherapy, EVAP portion====
 
−
*[[Etoposide (Vepesid)]]
 
−
*[[Vinblastine (Velban)]]
 
−
*[[Doxorubicin (Adriamycin)]]
 
−
====Glucocorticoid therapy, EVAP portion====
 
−
*[[Prednisone (Sterapred)]]
 
−
</div></div>
 
−
===References===
 
−
# Hancock BW, Vaughan Hudson G, Vaughan Hudson B, Bennett MH, MacLennan KA, Haybittle JL, Anderson L, Linch DC; BNLI. LOPP alternating with EVAP is superior to LOPP alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation trial. J Clin Oncol. 1992 Aug;10(8):1252-8. [https://doi.org/10.1200/JCO.1992.10.8.1252 link to original article] [https://pubmed.ncbi.nlm.nih.gov/1634914 PubMed]
 
−
# Hancock BW, Vaughan Hudson G, Vaughan Hudson B, Linch DC, Anderson L, MacLennan KA; BNLI. Hybrid LOPP/EVA is not better than LOPP alternating with EVAP: a prematurely terminated British National Lymphoma Investigation randomized trial. Ann Oncol. 1994;5 Suppl 2:117-20. [https://doi.org/10.1093/annonc/5.suppl_2.s117 link to original article] [https://pubmed.ncbi.nlm.nih.gov/8204511 PubMed]
 
−
==Mechlorethamine monotherapy {{#subobject:3674c2|Regimen=1}}==
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:2761c1|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
−
|-
 
−
|[https://jamanetwork.com/journals/jama/fullarticle/288442 Goodman et al. 1946]
 
−
|NR
 
−
| style="background-color:#91cf61" |Non-randomized
 
−
| style="background-color:#d3d3d3" |
 
−
| style="background-color:#d3d3d3" |
 
−
|-
 
−
|[https://jamanetwork.com/journals/jama/article-abstract/288767 Jacobson et al. 1946]
 
−
|1943-1945
 
−
| style="background-color:#91cf61" |Non-randomized
 
−
| style="background-color:#d3d3d3" |
 
−
| style="background-color:#d3d3d3" |
 
−
|-
 
−
|[https://doi.org/10.7326/0003-4819-27-4-529 Wintrobe et al. 1947]
 
−
|NR
 
−
| style="background-color:#91cf61" |Non-randomized
 
−
| style="background-color:#d3d3d3" |
 
−
| style="background-color:#d3d3d3" |
 
−
|-
 
−
|[https://doi.org/10.7326/0003-4819-30-2-381 Meyer & Overmiller 1949]
 
−
|1946-1947
 
−
| style="background-color:#91cf61" |Non-randomized
 
−
| style="background-color:#d3d3d3" |
 
−
| style="background-color:#d3d3d3" |
 
−
|-
 
−
|[https://jamanetwork.com/journals/jama/article-abstract/337835 Jacobs et al. 1968]
 
−
|1960-1963
 
−
| style="background-color:#1a9851" |Randomized (C)
 
−
|[[#Cyclophosphamide_monotherapy_99|Cyclophosphamide]]
 
−
| style="background-color:#ffffbf" |Seems not superior
 
−
|-
 
−
|}
 
−
''These references are of major historic interest as they are the first systemic chemotherapy trials in humans. Note that some of these early trials used nitrogen mustards other than mechlorethamine but are grouped here for simplicity.''
 
−
====Chemotherapy====
 
−
*[[Mechlorethamine (Mustargen)]]
 
−
</div></div>
 
−
===References===
 
−
# Goodman LS, Wintrobe MM, Dameshek W, Goodman MJ, Gilman A, McLennan MT. Nitrogen mustard therapy; use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. J Am Med Assoc. 1946 Sep 21;132:126-32. [https://jamanetwork.com/journals/jama/fullarticle/288442 link to original article] [https://pubmed.ncbi.nlm.nih.gov/20997191 PubMed]
 
−
# Jacobson LO, Spurr CL, Guzman-Barron ES, Smith T, Lushbaugh C, Dick GF. Nitrogen mustard therapy; studies on the effect of methyl-bis (beta-chloroethyl) amine hydrochloride on neoplastic diseases and allied disorders of the hemopoietic system. J Am Med Assoc. 1946 Oct 5;132:263-71. [https://jamanetwork.com/journals/jama/article-abstract/288767 link to original article] [https://pubmed.ncbi.nlm.nih.gov/20997209 PubMed]
 
−
# Wintrobe MM, Huguley CM Jr, McLennan MT, Penna de Carvalho Lima L. Nitrogen mustard as a therapeutic agent for Hodgkin's disease, lymphosarcoma and leukemia. Ann Intern Med. 1947 Oct;27(4):529-40. [https://doi.org/10.7326/0003-4819-27-4-529 link to original article] [https://pubmed.ncbi.nlm.nih.gov/20268426 PubMed]
 
−
# Meyer AH, Overmiller WC. The use of nitrogen mustard in Hodgkin's disease and lymphosarcoma. Ann Intern Med. 1949 Feb;30(2):381-6. [https://doi.org/10.7326/0003-4819-30-2-381 link to original article] [https://pubmed.ncbi.nlm.nih.gov/18109292 PubMed]
 
−
# Jacobs EM, Peters FC, Luce JK, Zippin C, Wood DA. Mechlorethamine HCl and cyclophosphamide in the treatment of Hodgkin's disease and the lymphomas. JAMA. 1968 Feb 5;203(6):392-8. [https://jamanetwork.com/journals/jama/article-abstract/337835 link to original article] [https://pubmed.ncbi.nlm.nih.gov/4865234 PubMed]
 
−
==MOPP/ABVD {{#subobject:f28468|Regimen=1}}==
 
−
MOPP/ABVD: '''<u>M</u>'''ustargen (Mechlorethamine), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone alternating with '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>V</u>'''inblastine, '''<u>D</u>'''acarbazine
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Protocol {{#subobject:5b28f5|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
−
|-
 
−
|[https://doi.org/10.1056/NEJM198204013061303 Santoro et al. 1982]
 
−
|1974-1980
 
−
| style="background-color:#1a9851" |Phase 3 (E-switch-ic)
 
−
|[[Hodgkin_lymphoma#MOPP|MOPP]]
 
−
| style="background-color:#1a9850" |Superior PFS
 
−
|-
 
−
|[https://doi.org/10.1200/jco.1994.12.2.279 Somers et al. 1994]
 
−
|1981-1986
 
−
| style="background-color:#1a9851" |Phase 3 (E-switch-ic)
 
−
|[[Hodgkin_lymphoma#MOPP|MOPP]]
 
−
| style="background-color:#91cf60" |Seems to have superior FFS
 
−
|-
 
−
| rowspan="2" |[https://doi.org/10.1056/NEJM199211193272102 Canellos et al. 1992 (CALGB 8251)]
 
−
|rowspan=2|1982-NR
 
−
| rowspan="2" style="background-color:#1a9851" |Phase 3 (E-switch-ic)
 
−
|1. [[Hodgkin_lymphoma#ABVD_3|ABVD]]
 
−
| style="background-color:#ffffbf" |Seems not superior<sup>1</sup>
 
−
|-
 
−
|2. [[Hodgkin_lymphoma#MOPP|MOPP]]
 
−
| style="background-color:#91cf60" |Seems to have superior EFS<sup>1</sup>
 
−
|-
 
−
|[https://doi.org/10.1200/jco.1996.14.5.1421 Viviani et al. 1996]
 
−
|1982-1990
 
−
| style="background-color:#1a9851" |Phase 3 (C)
 
−
|[[#MOPP-ABVD_99|MOPP-ABVD]]
 
−
| style="background-color:#ffffbf" |Seems not superior
 
−
|-
 
−
|[https://doi.org/10.1200/jco.1997.15.4.1638 Connor et al. 1997 (NCIC-CTG HD4)]
 
−
|1984-1989
 
−
| style="background-color:#1a9851" |Phase 3 (C)
 
−
|[[Hodgkin_lymphoma#MOPP-ABV_3|MOPP-ABV]]
 
−
| style="background-color:#ffffbf" |Seems not superior
 
−
|-
 
−
|[https://doi.org/10.1200/JCO.1998.16.3.897 Hutchinson et al. 1998 (CCG-521)]
 
−
|1986-1990
 
−
| style="background-color:#1a9851" |Phase 3 (C)
 
−
|[[Hodgkin_lymphoma#ABVD_3|ABVD]], then [[Hodgkin_lymphoma#Radiation_therapy_2|RT]]
 
−
| style="background-color:#fee08b" |Might have inferior EFS
 
−
|-
 
−
|}
 
−
''<sup>1</sup>Reported efficacy for CALGB 8251 is based on the 2009 update.''
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy, MOPP portion====
 
−
*[[Mechlorethamine (Mustargen)]]
 
−
*[[Vincristine (Oncovin)]]
 
−
*[[Procarbazine (Matulane)]]
 
−
====Glucocorticoid therapy, MOPP portion====
 
−
*[[Prednisone (Sterapred)]]
 
−
====Chemotherapy, ABVD portion====
 
−
*[[Doxorubicin (Adriamycin)]]
 
−
*[[Bleomycin (Blenoxane)]]
 
−
*[[Vinblastine (Velban)]]
 
−
*[[Dacarbazine (DTIC)]]
 
−
</div></div>
 
−
===References===
 
−
# Santoro A, Bonadonna G, Bonfante V, Valagussa P. Alternating drug combinations in the treatment of advanced Hodgkin's disease. N Engl J Med. 1982 Apr 1;306(13):770-5. [https://doi.org/10.1056/NEJM198204013061303 link to original article] [https://pubmed.ncbi.nlm.nih.gov/6174865 PubMed]
 
−
## '''Update:''' Bonadonna G, Valagussa P, Santoro A. Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease: a report of 8-year results. Ann Intern Med. 1986 Jun;104(6):739-46. [https://doi.org/10.7326/0003-4819-104-6-739 link to original article] [https://pubmed.ncbi.nlm.nih.gov/2422994 PubMed]
 
−
# '''CALGB 8251:''' Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, Green MR, Gottlieb A, Peterson BA. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992 Nov 19;327(21):1478-84. [https://doi.org/10.1056/NEJM199211193272102 link to original article] [https://pubmed.ncbi.nlm.nih.gov/1383821 PubMed]
 
−
## '''Update:''' Canellos GP, Niedzwiecki D. Long-term follow-up of Hodgkin's disease trial. N Engl J Med. 2002 May 2;346(18):1417-8. [https://doi.org/10.1056/NEJM200205023461821 link to original article] [https://pubmed.ncbi.nlm.nih.gov/11986425 PubMed]
 
−
## '''Update:''' Canellos GP, Niedzwiecki D, Johnson JL. Long-term follow-up of survival in Hodgkin's lymphoma. N Engl J Med. 2009 Dec 10;361(24):2390-1. [https://doi.org/10.1056/NEJMc0906731 link to original article] [https://pubmed.ncbi.nlm.nih.gov/20007568 PubMed]
 
−
# Somers R, Carde P, Henry-Amar M, Tarayre M, Thomas J, Hagenbeek A, Monconduit M, de Pauw BE, Breed WP, Verdonck L, Burgers JMV, Eghbali H, Zittoun R; [[Study_Groups#EORTC|EORTC]]. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organisation for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial. J Clin Oncol. 1994 Feb;12(2):279-87. [https://doi.org/10.1200/jco.1994.12.2.279 link to original article] [https://pubmed.ncbi.nlm.nih.gov/7509381 PubMed]
 
−
# Viviani S, Bonadonna G, Santoro A, Bonfante V, Zanini M, Devizzi L, Soncini F, Valagussa P. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results. J Clin Oncol. 1996 May;14(5):1421-30. [https://doi.org/10.1200/jco.1996.14.5.1421 link to original article] [https://pubmed.ncbi.nlm.nih.gov/8622055 PubMed]
 
−
# '''NCIC-CTG HD4:''' Connors JM, Klimo P, Adams G, Burns BF, Cooper I, Meyer RM, O'Reilly SE, Pater J, Quirt I, Sadura A, Shustik C, Skillings J, Sutcliffe S, Verma S, Yoshida S, Zee B. Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group. J Clin Oncol. 1997 Apr;15(4):1638-45. Erratum in: J Clin Oncol 1997 Jul;15(7):2762. [https://doi.org/10.1200/jco.1997.15.4.1638 link to original article] [https://pubmed.ncbi.nlm.nih.gov/9193364 PubMed]
 
−
# '''CCG-521:''' Hutchinson RJ, Fryer CJ, Davis PC, Nachman J, Krailo MD, O'Brien RT, Collins RD, Whalen T, Reardon D, Trigg ME, Gilchrist GS. MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin's disease in children: results of the Children's Cancer Group Phase III Trial. J Clin Oncol. 1998 Mar;16(3):897-906. [https://doi.org/10.1200/JCO.1998.16.3.897 link to original article] [https://pubmed.ncbi.nlm.nih.gov/9508171 PubMed]
 
−
==MVPP {{#subobject:b01f3a|Regimen=1}}==
 
−
MVPP: '''<u>M</u>'''echlorethamine, '''<u>V</u>'''inblastine, '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:312fd8|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
−
|-
 
−
|rowspan=3|[https://doi.org/10.1002/1097-0142(19800815)46:4%3C654::AID-CNCR2820460405%3E3.0.CO;2-A Cooper et al. 1980]
 
−
|rowspan=3|1972-1975
 
−
|rowspan=3 style="background-color:#1a9851"|Phase 3 (E-switch-ic)
 
−
|1. [[#COPP_.28CCNU.29|COPP]]
 
−
|style="background-color:#ffffbf"|Seems not superior
 
−
|-
 
−
|2. [[#CVPP|CVPP]]
 
−
|style="background-color:#ffffbf"|Seems not superior
 
−
|-
 
−
|3. [[Hodgkin_lymphoma#MOPP|MOPP]]
 
−
|style="background-color:#ffffbf"|Seems not superior
 
−
|-
 
−
|}
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Mechlorethamine (Mustargen)]]
 
−
*[[Vinblastine (Velban)]]
 
−
*[[Procarbazine (Matulane)]]
 
−
====Glucocorticoid therapy====
 
−
*[[Prednisone (Sterapred)]]
 
−
</div></div>
 
−
===References===
 
−
# Cooper MR, Pajak TF, Nissen NI, Stutzman L, Brunner K, Cuttner J, Falkson G, Grunwald H, Bank A, Leone L, Seligman BR, Silver RT, Weiss RB, Haurani F, Blom J, Spurr CL, Glidewell OJ, Gottlieb AJ, Holland JF. A new effective four-drug combination of CCNU (1-[2-chloroethyl]-3-cyclohexyl-1-nitrosourea) (NSC-79038), vinblastine, prednisone, and procarbazine for the treatment of advanced Hodgkin's disease. Cancer. 1980 Aug 15;46(4):654-62. [https://doi.org/10.1002/1097-0142(19800815)46:4%3C654::AID-CNCR2820460405%3E3.0.CO;2-A link to original article] [https://pubmed.ncbi.nlm.nih.gov/7397630 PubMed]
 
−
==NOVP {{#subobject:230457|Regimen=1}}==
 
−
NOVP: '''<u>N</u>'''ovantrone (Mitoxantrone), '''<u>O</u>'''ncovin (Vincristine), '''<u>V</u>'''inblastine, '''<u>P</u>'''rednisone
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:5bf81f|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
!style="width: 25%"|Study
 
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://pubmed.ncbi.nlm.nih.gov/2259922 Hagemeister et al. 1990]
 
−
|style="background-color:#91cf61"|Phase 2
 
−
|-
 
−
|}
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Mitoxantrone (Novantrone)]]
 
−
*[[Vincristine (Oncovin)]]
 
−
*[[Vinblastine (Velban)]]
 
−
====Glucocorticoid therapy====
 
−
*[[Prednisone (Sterapred)]]
 
−
</div></div>
 
−
===References===
 
−
# Hagemeister FB, Cabanillas F, Velásquez WS, Meistrich ML, Liang JC, McLaughlin P, Redman JR, Romaguera JE, Rodríguez MA, Swan F Jr, Fuller LM. NOVP: a novel chemotherapeutic regimen with minimal toxicity for treatment of Hodgkin's disease. Semin Oncol. 1990 Dec;17(6 Suppl 10):34-8. [https://mdanderson.elsevierpure.com/en/publications/novp-a-novel-chemotherapeutic-regimen-with-minimal-toxicity-for-t link to original article] [https://pubmed.ncbi.nlm.nih.gov/2259922 PubMed]
 
−
==SCAB {{#subobject:344883|Regimen=1}}==
 
−
SCAB: '''<u>S</u>'''treptozocin, '''<u>C</u>'''CNU (Lomustine), '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:a68d3b|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
!style="width: 25%"|Study
 
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://doi.org/10.1002/1097-0142(19810115)47:2%3C224::AID-CNCR2820470203%3E3.0.CO;2-6 Diggs et al. 1981]
 
−
|style="background-color:#91cf61"|Non-randomized
 
−
|-
 
−
|}
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Streptozocin (Zanosar)]]
 
−
*[[Lomustine (CCNU)]]
 
−
*[[Doxorubicin (Adriamycin)]]
 
−
*[[Bleomycin (Blenoxane)]]
 
−
</div></div>
 
−
===References===
 
−
# Diggs CH, Wiernik PH, Sutherland JC. Treatment of advanced untreated Hodgkin's disease with SCAB--an alternative to MOPP. Cancer. 1981 Jan 15;47(2):224-8. [https://doi.org/10.1002/1097-0142(19810115)47:2%3C224::AID-CNCR2820470203%3E3.0.CO;2-6 link to original article] [https://pubmed.ncbi.nlm.nih.gov/6161689 PubMed]
 
−
## '''Update:''' Wiernik PH, Schiffer CA. Long-term follow-up of advanced Hodgkin's disease patients treated with a combination of streptozotocin, lomustine (CCNU), doxorubicin and bleomycin (SCAB). J Cancer Res Clin Oncol. 1988;114(1):105-7. [https://doi.org/10.1007/bf00390494 link to original article] [https://pubmed.ncbi.nlm.nih.gov/2450876 PubMed]
 
−
==Vinblastine monotherapy {{#subobject:b1c2da|Regimen=1}}==
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:48bfd8|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
−
|-
 
−
|[https://jamanetwork.com/journals/jama/article-abstract/657749 Stutzman et al. 1966]
 
−
|1963-1964
 
−
|style="background-color:#1a9851"|Randomized (E-switch-ic)
 
−
|[[#Cyclophosphamide_monotherapy_88|Cyclophosphamide]]
 
−
| style="background-color:#1a9850" |Superior ORR
 
−
|-
 
−
|}
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Vinblastine (Velban)]]
 
−
</div></div>
 
−
===References===
 
−
# Stutzman L, Ezdinli EZ, Stutzman MA. Vinblastine sulfate vs cyclophosphamide in the therapy for lymphoma. JAMA. 1966 Jan 17;195(3):173-8. [https://jamanetwork.com/journals/jama/article-abstract/657749 link to original article] [https://pubmed.ncbi.nlm.nih.gov/5322863 PubMed]
 
−
==OPPA {{#subobject:6418c0|Regimen=1}}==
 
−
OPPA: '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone, '''<u>A</u>'''driamycin (Doxorubicin)
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:e17569|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 60%; text-align:center;"
 
−
! style="width: 33%" |Study
 
−
! style="width: 33%" |Years of enrollment
 
−
! style="width: 33%" |[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://doi.org/10.1200/jco.2009.26.9381 Mauz-Körholz et al. 2010 (GPOH-HD-2002)]
 
−
|2002-2005
 
−
| style="background-color:#91cf61" | Phase II
 
−
|-
 
−
|}
 
−
''This regimen is meant for girls. Patients with early-stage disease only received the OPPA portion, see text for details.''
 
−
====Chemotherapy====
 
−
*[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> IV once per day on days 1, 8, 15
 
−
*[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 15
 
−
*[[Doxorubicin (Adriamycin)]] 40 mg/m<sup>2</sup> IV once per day on days 1 & 15
 
−
====Glucocorticoid therapy====
 
−
*[[Prednisone (Sterapred)]] 60 mg/m<sup>2</sup> PO once per day on days 1 to 15
 
−
'''28-day cycle for 2 cycles'''
 
−
</div>
 
−
<div class="toccolours" style="background-color:#cbd5e7">
 
−
====Subsequent treatment====
 
−
*Treatment group 2: [[#C-MOPP|COPP]] x 2
 
−
*Treatment group 3: [[#C-MOPP|COPP]] x 4
 
−
</div></div>
 
−
===References===
 
−
#'''GPOH-HD-2002:''' Mauz-Körholz C, Hasenclever D, Dörffel W, Ruschke K, Pelz T, Voigt A, Stiefel M, Winkler M, Vilser C, Dieckmann K, Karlén J, Bergsträsser E, Fosså A, Mann G, Hummel M, Klapper W, Stein H, Vordermark D, Kluge R, Körholz D. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol. 2010 Aug 10;28(23):3680-6. Epub 2010 Jul 12. [https://doi.org/10.1200/jco.2009.26.9381 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/20625128 PubMed] NCT00416832
 
−
==VAMP (Methotrexate) {{#subobject:4d666a|Regimen=1}}==
 
−
VAMP: '''<u>V</u>'''inblastine, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>M</u>'''ethrotrexate, '''<u>P</u>'''rednisone
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:6f694d|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
! style="width: 25%" |Study
 
−
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3526806/ Metzger et al. 2012 (HOD99)]
 
−
| style="background-color:#91cf61" |Phase 2
 
−
|-
 
−
|}
 
−
''To be completed? This is to be distinguished from the VAMP protocols used in AML and multiple myeloma.''
 
−
====Chemotherapy====
 
−
*[[Vinblastine (Velban)]]
 
−
*[[Doxorubicin (Adriamycin)]]
 
−
*[[Methotrexate (MTX)]]
 
−
====Glucocorticoid therapy====
 
−
*[[Prednisone (Sterapred)]]
 
−
'''4 cycles'''
 
−
</div>
 
−
<div class="toccolours" style="background-color:#cbd5e7">
 
−
====Subsequent treatment====
 
−
*Early responders: [[Hodgkin_lymphoma_-_null_regimens#Observation|Observation]] versus [[#Radiation_therapy_2|RT]]
 
−
</div></div>
 
−
===References===
 
−
#'''HOD99:''' Metzger ML, Weinstein HJ, Hudson MM, Billett AL, Larsen EC, Friedmann A, Howard SC, Donaldson SS, Krasin MJ, Kun LE, Marcus KJ, Yock TI, Tarbell N, Billups CA, Wu J, Link MP. Association between radiotherapy vs no radiotherapy based on early response to VAMP chemotherapy and survival among children with favorable-risk Hodgkin lymphoma. JAMA. 2012 Jun 27;307(24):2609-16. [https://jamanetwork.com/journals/jama/fullarticle/1199151 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3526806/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/22735430 PubMed]
 
−
==ABVE {{#subobject:c24h71|Regimen=1}}==
 
−
ABVE: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>V</u>'''incristine, '''<u>E</u>'''toposide
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:7fa7ya|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 60%; text-align:center;"
 
−
! style="width: 33%" |Study
 
−
! style="width: 33%" |Years of enrollment
 
−
! style="width: 33%" |[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc3468662/ Tebbi et al. 2012 (POG P9426)]
 
−
|1996-2001
 
−
| style="background-color:#91cf61" |Non-randomized (see note)
 
−
|-
 
−
|}
 
−
''Note: this trial had a randomization to receive or not receive dexrazoxane. Labeled here as non-randomized because this drug does not have antineoplastic properties.''
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once per day on days 1 & 15
 
−
*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once per day on days 1 & 15
 
−
*[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once per day on days 1 & 15
 
−
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV once per day on days 1 to 5
 
−
====Supportive therapy====
 
−
*[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day on days 6 to 14, then once per day on days 16 until ANC greater than 1000/uL
 
−
'''28-day cycle for 2 cycles'''
 
−
</div>
 
−
<div class="toccolours" style="background-color:#cbd5e7">
 
−
====Subsequent treatment====
 
−
*CR: [[#Radiation_therapy_2|IFRT]] consolidation
 
−
*Other than CR: [[#ABVE|ABVE]] x 2, then [[#Radiation_therapy_2|IFRT]] consolidation
 
−
</div></div>
 
−
===References===
 
−
#'''POG P9426:''' Tebbi CK, Mendenhall NP, London WB, Williams JL, Hutchison RE, Fitzgerald TJ, de Alarcón PA, Schwartz C, Chauvenet A. Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2012 Dec 15;59(7):1259-65. Epub 2012 Aug 21. [https://doi.org/10.1002/pbc.24279 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc3468662/ link to PMC article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/22911615/ PubMed] NCT00002827
 
−
==MOPP {{#subobject:bcde0|Regimen=1}}==
 
−
MOPP: '''<u>M</u>'''echlorethamine, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone
 
−
</div></div><br>
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen variant #3, uncapped vincristine {{#subobject:ff7478|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 60%; text-align:center;"
 
−
!style="width: 33%"|Study
 
−
!style="width: 33%"|Years of enrollment
 
−
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[http://www.bloodjournal.org/content/42/2/163.long Young et al. 1973a]
 
−
|1964-NR
 
−
| style="background-color:#91cf61" |Non-randomized (RT)
 
−
|-
 
−
|[https://doi.org/10.1002/1097-0142(197610)38:4%3C1494::AID-CNCR2820380408%3E3.0.CO;2-E Kolygin 1976]
 
−
|1970-1975
 
−
| style="background-color:#91cf61" |Non-randomized (RT)
 
−
|-
 
−
|}
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Mechlorethamine (Mustargen)]] 6 mg/m<sup>2</sup> IV once per day on days 1 & 8
 
−
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> IV once per day on days 1 & 8
 
−
*[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 14
 
−
====Glucocorticoid therapy====
 
−
*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 14
 
−
'''28-day cycle for 6 to 8 cycles'''
 
−
</div></div>
 
−
===References===
 
−
#Young RC, DeVita VT, Johnson RE. Hodgkin's disease in childhood. Blood. 1973 Aug;42(2):163-74. [http://www.bloodjournal.org/content/42/2/163.long link to original article] [https://pubmed.ncbi.nlm.nih.gov/4793108 PubMed]
 
−
#Kolygin BA. Combination chemotherapy of Hodgkin's disease in children. Cancer. 1976 Oct;38(4):1494-7. [https://doi.org/10.1002/1097-0142(197610)38:4%3C1494::AID-CNCR2820380408%3E3.0.CO;2-E link to original article] [https://pubmed.ncbi.nlm.nih.gov/991072 PubMed]
 
−
=Consolidation after upfront therapy=
 
−
==C-MOPP {{#subobject:034931|Regimen=1}}==
 
−
C-MOPP: '''<u>C</u>'''yclophospha'''<u>M</u>'''ide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone
 
−
<br>COPP: '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen variant #1, 2 cycles {{#subobject:cfcc4b|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 60%; text-align:center;"
 
−
! style="width: 33%" |Study
 
−
! style="width: 33%" |Years of enrollment
 
−
! style="width: 33%" |[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://doi.org/10.1200/jco.2009.26.9381 Mauz-Körholz et al. 2010 (GPOH-HD-2002)]
 
−
|2002-2005
 
−
| style="background-color:#91cf61" |Phase 2
 
−
|-
 
−
|}
 
−
<div class="toccolours" style="background-color:#cbd5e8">
 
−
====Preceding treatment====
 
−
*[[#OPPA|OPPA]] x 2
 
−
</div>
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> IV once per day on days 1 & 8
 
−
*[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> IV once per day on days 1 & 8
 
−
*[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 15
 
−
====Glucocorticoid therapy====
 
−
*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 15
 
−
'''28-day cycle for 2 cycles'''
 
−
</div></div><br>
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen variant #2, 4 cycles {{#subobject:228db9|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 60%; text-align:center;"
 
−
! style="width: 33%" |Study
 
−
! style="width: 33%" |Years of enrollment
 
−
! style="width: 33%" |[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://doi.org/10.1200/jco.2009.26.9381 Mauz-Körholz et al. 2010 (GPOH-HD-2002)]
 
−
|2002-2005
 
−
| style="background-color:#91cf61" |Phase 2
 
−
|-
 
−
|}
 
−
<div class="toccolours" style="background-color:#cbd5e8">
 
−
====Preceding treatment====
 
−
*[[#OPPA|OPPA]] x 2
 
−
</div>
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> IV once per day on days 1 & 8
 
−
*[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> IV once per day on days 1 & 8
 
−
*[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 15
 
−
====Glucocorticoid therapy====
 
−
*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 15
 
−
'''28-day cycle for 4 cycles'''
 
−
</div></div>
 
−
===References===
 
−
#'''GPOH-HD-2002:''' Mauz-Körholz C, Hasenclever D, Dörffel W, Ruschke K, Pelz T, Voigt A, Stiefel M, Winkler M, Vilser C, Dieckmann K, Karlén J, Bergsträsser E, Fosså A, Mann G, Hummel M, Klapper W, Stein H, Vordermark D, Kluge R, Körholz D. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol. 2010 Aug 10;28(23):3680-6. Epub 2010 Jul 12. [https://doi.org/10.1200/jco.2009.26.9381 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/20625128 PubMed] NCT00416832
 
−
==COPDAC {{#subobject:195ad7|Regimen=1}}==
 
−
COPDAC: '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone, '''<u>DAC</u>'''arbazine
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen variant #1, 2 cycles {{#subobject:e9d06d|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 60%; text-align:center;"
 
−
! style="width: 33%" |Study
 
−
! style="width: 33%" |Years of enrollment
 
−
! style="width: 33%" |[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://doi.org/10.1200/jco.2009.26.9381 Mauz-Körholz et al. 2010 (GPOH-HD-2002)]
 
−
|2002-2005
 
−
| style="background-color:#91cf61" |Phase 2
 
−
|-
 
−
|}
 
−
<div class="toccolours" style="background-color:#cbd5e8">
 
−
====Preceding treatment====
 
−
*[[#OEPA|OEPA]] x 2
 
−
</div>
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> IV once per day on days 1 & 8
 
−
*[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> IV once per day on days 1 & 8
 
−
*[[Dacarbazine (DTIC)]] 250 mg/m<sup>2</sup> IV once per day on days 1 to 4
 
−
====Glucocorticoid therapy====
 
−
*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 15
 
−
'''28-day cycle for 2 cycles'''
 
−
</div></div><br>
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen variant #2, 4 cycles {{#subobject:515d30|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 60%; text-align:center;"
 
−
! style="width: 33%" |Study
 
−
! style="width: 33%" |Years of enrollment
 
−
! style="width: 33%" |[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://doi.org/10.1200/jco.2009.26.9381 Mauz-Körholz et al. 2010 (GPOH-HD-2002)]
 
−
|2002-2005
 
−
| style="background-color:#91cf61" |Phase 2
 
−
|-
 
−
|}
 
−
<div class="toccolours" style="background-color:#cbd5e8">
 
−
====Preceding treatment====
 
−
*[[#OEPA|OEPA]] x 2
 
−
</div>
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> IV once per day on days 1 & 8
 
−
*[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> IV once per day on days 1 & 8
 
−
*[[Dacarbazine (DTIC)]] 250 mg/m<sup>2</sup> IV once per day on days 1 to 4
 
−
====Glucocorticoid therapy====
 
−
*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 15
 
−
'''28-day cycle for 4 cycles'''
 
−
</div></div>
 
−
===References ===
 
−
#'''GPOH-HD-2002:''' Mauz-Körholz C, Hasenclever D, Dörffel W, Ruschke K, Pelz T, Voigt A, Stiefel M, Winkler M, Vilser C, Dieckmann K, Karlén J, Bergsträsser E, Fosså A, Mann G, Hummel M, Klapper W, Stein H, Vordermark D, Kluge R, Körholz D. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol. 2010 Aug 10;28(23):3680-6. Epub 2010 Jul 12. [https://doi.org/10.1200/jco.2009.26.9381 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/20625128 PubMed] NCT00416832
 
−
=Maintenance after upfront therapy=
 
−
==Bacillus Calmette-Guérin (BCG) monotherapy {{#subobject:e1fd72|Regimen=1}}==
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:52ca75|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
! style="width: 20%" |Study
 
−
! style="width: 20%" |Years of enrollment
 
−
! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
 
−
! style="width: 20%" |Comparator
 
−
! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
−
|-
 
−
|[https://doi.org/10.1056/NEJM197412052912305 Sokal et al. 1974]
 
−
|1965-1967
 
−
| style="background-color:#91cf61" |Randomized, <20 pts in this subgroup (E-esc)
 
−
|[[Hodgkin_lymphoma_-_null_regimens#Observation_2|Observation]]
 
−
| style="background-color:#1a9850" |Superior PFS
 
−
|-
 
−
|}
 
−
''Note: this study was open to patients with "malignant lymphoma" but the majority had Hodgkin disease.''
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Immunotherapy====
 
−
*[[Bacillus Calmette-Guérin (BCG)]]
 
−
</div></div>
 
−
===References===
 
−
#Sokal JE, Aungst CW, Snyderman M. Delay in progression of malignant lymphoma after BCG vaccination. N Engl J Med. 1974 Dec 5;291(23):1226-30. [https://doi.org/10.1056/NEJM197412052912305 link to original article] [https://pubmed.ncbi.nlm.nih.gov/4609380 PubMed]
 
−
=Relapsed or refractory, salvage therapy =
 
−
==ABDIC {{#subobject:c5c5ab|Regimen=1}}==
 
−
ABDIC: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>DI</u>'''C (Dacarbazine), '''<u>C</u>'''CNU (Lomustine), Prednisone
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:4ba1e1|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
! style="width: 25%" |Study
 
−
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://doi.org/10.1002/1097-0142(19801201)46:11%3C2349::AID-CNCR2820461105%3E3.0.CO;2-V Rodgers et al. 1980]
 
−
| style="background-color:#91cf61" |Phase 2
 
−
|-
 
−
|}
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Doxorubicin (Adriamycin)]]
 
−
*[[Bleomycin (Blenoxane)]]
 
−
*[[Dacarbazine (DTIC)]]
 
−
*[[Lomustine (CCNU)]]
 
−
====Glucocorticoid therapy====
 
−
*[[Prednisone (Sterapred)]]
 
−
</div></div>
 
−
===References===
 
−
#Rodgers RW, Gamble JF, Loh KK, Shullenberger CC. Adriamycin, bleomycin, DIC, CCNU, and prednisone (ABDIC) chemotherapy in MOPP-resistant Hodgkin's disease. Cancer. 1980 Dec 1;46(11):2349-55. [https://doi.org/10.1002/1097-0142(19801201)46:11%3C2349::AID-CNCR2820461105%3E3.0.CO;2-V link to original article] [https://pubmed.ncbi.nlm.nih.gov/6159961 PubMed]
 
−
##'''Update:''' Tannir N, Hagemeister F, Velasquez W, Cabanillas F. Long-term follow-up with ABDIC salvage chemotherapy of MOPP-resistant Hodgkin's disease. J Clin Oncol. 1983 Jul;1(7):432-9. [https://doi.org/10.1200/jco.1983.1.7.432 link to original article] [https://pubmed.ncbi.nlm.nih.gov/6199478 PubMed]
 
−
==ABVD {{#subobject:c5a35d|Regimen=1}}==
 
−
ABVD: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>V</u>'''inblastine, '''<u>D</u>'''acarbazine
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:ae32ee|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
! style="width: 25%" | Study
 
−
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://doi.org/10.1002/1097-0142(197806)41:6%3C2107::AID-CNCR2820410606%3E3.0.CO;2-L Krikorian et al. 1978]
 
−
| style="background-color:#91cf61" |Phase 2
 
−
|-
 
−
|[https://doi.org/10.1007/bf00254081 Santoro & Bonadonna 1979]
 
−
| style="background-color:#91cf61" | Non-randomized
 
−
|-
 
−
|[https://doi.org/10.7326/0003-4819-96-2-139 Santoro et al. 1982a]
 
−
| style="background-color:#91cf61" |Non-randomized
 
−
|-
 
−
|[https://doi.org/10.7326/0003-4819-101-4-440 Harker et al. 1984]
 
−
| style="background-color:#91cf61" |Non-randomized
 
−
|-
 
−
|}
 
−
''This is for historical interest only; ABVD is no longer used in the salvage setting.''
 
−
====Chemotherapy====
 
−
*[[Doxorubicin (Adriamycin)]]
 
−
*[[Bleomycin (Blenoxane)]]
 
−
*[[Vinblastine (Velban)]]
 
−
*[[Dacarbazine (DTIC)]]
 
−
</div></div>
 
−
===References===
 
−
#Krikorian JG, Portlock CS, Rosenberg SA. Treatment of advanced Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide (ABVD) after failure of MOPP therapy. Cancer. 1978 Jun;41(6):2107-11. [https://doi.org/10.1002/1097-0142(197806)41:6%3C2107::AID-CNCR2820410606%3E3.0.CO;2-L link to original article] [https://pubmed.ncbi.nlm.nih.gov/77716 PubMed]
 
−
#Santoro A, Bonadonna G. Prolonged disease-free survival in MOPP-resistant Hodgkin's disease after treatment with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD). Cancer Chemother Pharmacol. 1979;2(2):101-5. [https://doi.org/10.1007/bf00254081 link to original article] [https://pubmed.ncbi.nlm.nih.gov/93984 PubMed]
 
−
#Santoro A, Bonfante V, Bonadonna G. Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin's disease. Ann Intern Med. 1982 Feb;96(2):139-43. [https://doi.org/10.7326/0003-4819-96-2-139 link to original article] [https://pubmed.ncbi.nlm.nih.gov/6174060 PubMed]
 
−
#Harker WG, Kushlan P, Rosenberg SA. Combination chemotherapy for advanced Hodgkin's disease after failure of MOPP: ABVD and B-CAVe. Ann Intern Med. 1984 Oct;101(4):440-6. [https://doi.org/10.7326/0003-4819-101-4-440 link to original article] [https://pubmed.ncbi.nlm.nih.gov/6206757 PubMed]
 
−
==B-CAVe {{#subobject:41a31c|Regimen=1}}==
 
−
B-CAVe: '''<u>B</u>'''leomycin, '''<u>C</u>'''CNU (Lomustine), '''<u>A</u>'''driamycin (Doxorubicin), '''<u>V</u>'''inblastin'''<u>e</u>'''
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:c53f0c|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
! style="width: 25%" |Study
 
−
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://doi.org/10.1002/1097-0142(197805)41:5%3C1670::AID-CNCR2820410504%3E3.0.CO;2-Y Porzig et al. 1978]
 
−
| style="background-color:#91cf61" |Non-randomized
 
−
|-
 
−
|[https://doi.org/10.7326/0003-4819-101-4-440 Harker et al. 1984]
 
−
| style="background-color:#91cf61" |Non-randomized
 
−
|-
 
−
|}
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Bleomycin (Blenoxane)]]
 
−
*[[Lomustine (CCNU)]]
 
−
*[[Doxorubicin (Adriamycin)]]
 
−
*[[Vinblastine (Velban)]]
 
−
</div></div>
 
−
===References===
 
−
#Porzig KJ, Portlock CS, Robertson A, Rosenberg SA. Treatment of advanced Hodgkin's disease with B-CAVE following MOPP failure. Cancer. 1978 May;41(5):1670-5. [https://doi.org/10.1002/1097-0142(197805)41:5%3C1670::AID-CNCR2820410504%3E3.0.CO;2-Y link to original article] [https://pubmed.ncbi.nlm.nih.gov/77180 PubMed]
 
−
#Harker WG, Kushlan P, Rosenberg SA. Combination chemotherapy for advanced Hodgkin's disease after failure of MOPP: ABVD and B-CAVe. Ann Intern Med. 1984 Oct;101(4):440-6. [https://doi.org/10.7326/0003-4819-101-4-440 link to original article] [https://pubmed.ncbi.nlm.nih.gov/6206757 PubMed]
 
−
==BVCPP {{#subobject:cb42cf|Regimen=1}}==
 
−
BVCPP: '''<u>B</u>'''CNU (Carmustine), '''<u>V</u>'''inblastine, '''<u>C</u>'''yclophosphamide, '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:514e7d|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 60%; text-align:center;"
 
−
!style="width: 33%"|Study
 
−
!style="width: 33%"|Years of enrollment
 
−
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://doi.org/10.1002/1097-0142%28197811%2942%3A5%3C2101%3A%3AAID-CNCR2820420504%3E3.0.CO%3B2-M Durant et al. 1978]
 
−
|1971-1975
 
−
| style="background-color:#91cf61" |Non-randomized portion of RCT
 
−
|-
 
−
|}
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Carmustine (BCNU)]]
 
−
*[[Vinblastine (Velban)]]
 
−
*[[Cyclophosphamide (Cytoxan)]]
 
−
*[[Procarbazine (Matulane)]]
 
−
====Glucocorticoid therapy====
 
−
*[[Prednisone (Sterapred)]]
 
−
</div>
 
−
<div class="toccolours" style="background-color:#cbd5e7">
 
−
====Subsequent treatment====
 
−
*Patients who achieved CR: No additional therapy versus [[Hodgkin_lymphoma#MOPP|MOPP]] x 6 versus BVCPP x 6 additional cycles
 
−
</div></div>
 
−
===References===
 
−
#Durant JR, Gams RA, Velez-Garcia E, Bartolucci A, Wirtschafter D, Dorfman R. BCNU, velban, cyclophosphamide, procarbazine, and prednisone (BVCPP) in advanced Hodgkin's disease. Cancer. 1978 Nov;42(5):2101-10. [https://doi.org/10.1002/1097-0142%28197811%2942%3A5%3C2101%3A%3AAID-CNCR2820420504%3E3.0.CO%3B2-M link to original article] [https://pubmed.ncbi.nlm.nih.gov/719600 PubMed]
 
−
==BVDS {{#subobject:3a24f9|Regimen=1}}==
 
−
BVDS: '''<u>B</u>'''leomycin, '''<u>V</u>'''inblastine, '''<u>D</u>'''oxorubicin, '''<u>S</u>'''treptozocin
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:41d09e|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
! style="width: 25%" |Study
 
−
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://jamanetwork.com/journals/jama/article-abstract/350618 Vinciguerra et al. 1977]
 
−
| style="background-color:#ffffbe" |Non-randomized, <20 pts
 
−
|-
 
−
|}
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Bleomycin (Blenoxane)]]
 
−
*[[Vinblastine (Velban)]]
 
−
*[[Doxorubicin (Adriamycin)]]
 
−
*[[Streptozocin (Zanosar)]]
 
−
</div></div>
 
−
===References===
 
−
#Vinciguerra V, Coleman M, Jarowski CI, Degnan TJ, Silver RT. A new combination chemotherapy for resistant Hodgkin disease. JAMA. 1977 Jan 3;237(1):33-5. [https://jamanetwork.com/journals/jama/article-abstract/350618 link to original article] [https://pubmed.ncbi.nlm.nih.gov/62854 PubMed]
 
−
==CEP {{#subobject:a1a2cc|Regimen=1}}==
 
−
CEP: '''<u>C</u>'''CNU (Lomustine), '''<u>E</u>'''toposide, '''<u>P</u>'''rednimustine
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:a353e9|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
! style="width: 25%" |Study
 
−
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://pubmed.ncbi.nlm.nih.gov/2420012 Santoro et al. 1986]
 
−
| style="background-color:#91cf61" |Non-randomized
 
−
|-
 
−
|}
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Lomustine (CCNU)]]
 
−
*[[Etoposide (Vepesid)]]
 
−
*[[Prednimustine (Stereocyt)]]
 
−
</div></div>
 
−
===References===
 
−
#Santoro A, Viviani S, Valagussa P, Bonfante V, Bonadonna G. CCNU, etoposide, and prednimustine (CEP) in refractory Hodgkin's disease. Semin Oncol. 1986 Mar;13(1 Suppl 1):23-6. [https://pubmed.ncbi.nlm.nih.gov/2420012 PubMed]
 
−
==CVB {{#subobject:b2b2cc|Regimen=1}}==
 
−
CVB: '''<u>C</u>'''CNU (Lomustine), '''<u>V</u>'''inblastine, '''<u>B</u>'''leomycin
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:a464e9|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
! style="width: 25%" |Study
 
−
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://doi.org/10.1016/S0140-6736(75)92069-3 Goldman & Dawson 1975]
 
−
| style="background-color:#91cf61" |Non-randomized
 
−
|-
 
−
|}
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Lomustine (CCNU)]]
 
−
*[[Vinblastine (Velban)]]
 
−
*[[Bleomycin (Blenoxane)]]
 
−
</div></div>
 
−
===References===
 
−
#Goldman JM, Dawson AA. Combination therapy for advanced resistant Hodgkin's disease. Lancet. 1975 Dec 20;2(7947):1224-7. [https://doi.org/10.1016/S0140-6736(75)92069-3 link to original article] [https://pubmed.ncbi.nlm.nih.gov/53720 PubMed]
 
−
==CVPP {{#subobject:be8f99|Regimen=1}}==
 
−
CVPP: '''<u>C</u>'''CNU (Lomustine), '''<u>V</u>'''inblastine, '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:f32d98|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
! style="width: 20%" |Study
 
−
! style="width: 20%" |Years of enrollment
 
−
! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
 
−
! style="width: 20%" |Comparator
 
−
! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
−
|-
 
−
|[https://doi.org/10.1200/JCO.1986.4.6.838 Vinciguerra et al. 1986]
 
−
|1975-1981
 
−
| style="background-color:#1a9851" |Randomized (C)
 
−
|1. [[#ABOS_99|ABOS]]<br>2. [[#CVPP.2FABOS_99|CVPP/ABOS]]
 
−
| style="background-color:#ffffbf" |Seems not superior
 
−
|-
 
−
|}
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Lomustine (CCNU)]]
 
−
*[[Vinblastine (Velban)]]
 
−
*[[Procarbazine (Matulane)]]
 
−
====Glucocorticoid therapy====
 
−
*[[Prednisone (Sterapred)]]
 
−
</div></div>
 
−
===References===
 
−
#Vinciguerra V, Propert KJ, Coleman M, Anderson JR, Stutzman L, Pajak TF, Nissen NI, Frizzera G, Gottlieb A, Holland JF; [[Study_Groups#CALGB|CALGB]]. Alternating cycles of combination chemotherapy for patients with recurrent Hodgkin's disease following radiotherapy: a prospectively randomized study by the Cancer and Leukemia Group B. J Clin Oncol. 1986 Jun;4(6):838-46. [https://doi.org/10.1200/JCO.1986.4.6.838 link to original article] [https://pubmed.ncbi.nlm.nih.gov/2423652 PubMed]
 
−
==SCAB {{#subobject:04355f|Regimen=1}}==
 
−
SCAB: '''<u>S</u>'''treptozocin, '''<u>C</u>'''CNU (Lomustine), '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:5c34db|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
! style="width: 25%" |Study
 
−
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://doi.org/10.1002/mpo.2950030106 Levi et al. 1977]
 
−
| style="background-color:#ffffbe" |Non-randomized, <20 pts
 
−
|-
 
−
|}
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Streptozocin (Zanosar)]]
 
−
*[[Lomustine (CCNU)]]
 
−
*[[Doxorubicin (Adriamycin)]]
 
−
*[[Bleomycin (Blenoxane)]]
 
−
</div></div>
 
−
===References===
 
−
#Levi JA, Wiernik PH, Diggs CH. Combination chemotherapy of advanced previously treated Hodgkin's disease with streptozotocin, CCNU, adriamycin and bleomycin. Med Pediatr Oncol. 1977;3(1):33-40. [https://doi.org/10.1002/mpo.2950030106 link to original article] [https://pubmed.ncbi.nlm.nih.gov/65727 PubMed]
 
−
=Relapsed or refractory, further lines of therapy=
 
−
==Carmustine monotherapy {{#subobject:f072cf|Regimen=1}}==
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:d61e28|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
! style="width: 25%" |Study
 
−
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://doi.org/10.1056/NEJM197108262850902 Young et al. 1971]
 
−
| style="background-color:#91cf61" |Non-randomized
 
−
|-
 
−
|}
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Carmustine (BCNU)]]
 
−
</div></div>
 
−
===References===
 
−
#Young RC, DeVita VT Jr, Serpick AA, Canellos GP. Treatment of advanced Hodgkin's disease with (1,3 bis (2-chloroethyl)-1-nitrosourea) BCNU. N Engl J Med. 1971 Aug 26;285(9):475-9. [https://doi.org/10.1056/NEJM197108262850902 link to original article] [https://pubmed.ncbi.nlm.nih.gov/5558887 PubMed]
 
−
==Doxorubicin & Lomustine {{#subobject:7e7049|Regimen=1}}==
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:e9f038|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
! style="width: 25%" |Study
 
−
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://jamanetwork.com/journals/jama/article-abstract/355977 Williams & Einhorn 1977]
 
−
| style="background-color:#ffffbe" |Non-randomized, <20 pts
 
−
|-
 
−
|}
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Doxorubicin (Adriamycin)]]
 
−
*[[Lomustine (CCNU)]]
 
−
</div></div>
 
−
===References===
 
−
#Williams SD, Einhorn LH. Combination chemotherapy with doxorubicin and lomustine: treatment of refractory Hodgkin's disease. JAMA. 1977 Oct 10;238(15):1659-61. [https://jamanetwork.com/journals/jama/article-abstract/355977 link to original article] [https://pubmed.ncbi.nlm.nih.gov/578254 PubMed]
 
−
==Panobinostat monotherapy {{#subobject:ba10d6|Regimen=1}}==
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:0c34a8|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 80%; text-align:center;"
 
−
!style="width: 25%"|Study
 
−
!style="width: 25%"|Years of enrollment
 
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
 
−
|-
 
−
|[https://doi.org/10.1200/jco.2011.38.1350 Younes et al. 2012 (CLBH589E2214)]
 
−
|2008-2009
 
−
| style="background-color:#91cf61" |Phase 2
 
−
|Investigator assessment: 27% <br>Central review: 22%
 
−
|-
 
−
|}
 
−
''Patients had progressed after auto HSCT and had a median of 4 prior systemic regimens (range 2 to 7).''
 
−
====Targeted therapy====
 
−
*[[Panobinostat (Farydak)]] 40 mg PO three times per week (e.g., MWF)
 
−
'''21-day cycles'''
 
−
</div></div>
 
−
===References===
 
−
# '''CLBH589E2214:''' Younes A, Sureda A, Ben-Yehuda D, Zinzani PL, Ong TC, Prince HM, Harrison SJ, Kirschbaum M, Johnston P, Gallagher J, Le Corre C, Shen A, Engert A. Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol. 2012 Jun 20;30(18):2197-203. Epub 2012 Apr 30. [https://doi.org/10.1200/jco.2011.38.1350 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/22547596 PubMed] NCT00742027
 
−
==Sirolimus & Vorinostat {{#subobject:273a59|Regimen=1}}==
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:91d698|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 60%; text-align:center;"
 
−
!style="width: 33%"|Study
 
−
!style="width: 33%"|Years of enrollment
 
−
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://doi.org/10.1158/1078-0432.ccr-20-1215 Janku et al. 2020 (MDACC 2009-0729)]
 
−
|2010-2015
 
−
| style="background-color:#91cf61" |Non-randomized
 
−
|-
 
−
|}
 
−
''This is a very heavily pre-treated cohort, median of 6 prior therapies; doses here are one level below MTD and are proposed as the ongoing doses to be studied.''
 
−
====Immunosuppressive therapy====
 
−
*[[Sirolimus (Rapamune)]] 4 mg PO once per day
 
−
====Targeted therapy====
 
−
*[[Vorinostat (Zolinza)]] as follows:
 
−
**Cycle 1: 300 mg PO once per day on days 7 to 28
 
−
**Subsequent cycles: 300 mg PO once per day on days 1 to 28
 
−
'''28-day cycles'''
 
−
</div></div>
 
−
===References===
 
−
#'''MDACC 2009-0729:''' Janku F, Park H, Call SG, Madwani K, Oki Y, Subbiah V, Hong DS, Naing A, Velez-Bravo VM, Barnes TG, Hagemeister FB, Falchook GS, Karp DD, Wheler JJ, Piha-Paul SA, Garrido-Laguna I, Shpall EJ, Fayad LE, Neelapu SS, Meric-Bernstam F, Kurzrock R, Fanale MA. Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma. Clin Cancer Res. 2020 Nov 1;26(21):5579-5587. Epub 2020 Oct 14. [https://doi.org/10.1158/1078-0432.ccr-20-1215 link to original article] [https://pubmed.ncbi.nlm.nih.gov/33055173/ PubMed] NCT01087554
 
−
[[Category:Hodgkin lymphoma regimens]]
 
−
[[Category:Historical regimens]]
 
−
[[Category:Disease-specific pages]]
 
−
[[Category:Aggressive lymphomas]]
 

Latest revision as of 00:13, 18 June 2023

Retrieved from "https://hemonc.org/w/index.php?title=Staging_page&oldid=73776"